6HN Stock Overview
A biopharmaceutical company, engages in discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Everest Medicines Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$4.40 |
| 52 Week High | HK$4.60 |
| 52 Week Low | HK$1.65 |
| Beta | 1.94 |
| 11 Month Change | 13.99% |
| 3 Month Change | 92.98% |
| 1 Year Change | 84.87% |
| 33 Year Change | 3.77% |
| 5 Year Change | n/a |
| Change since IPO | -57.28% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6HN | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 9.5% | -0.7% | 0.2% |
| 1Y | 84.9% | -17.2% | 8.5% |
Return vs Industry: 6HN exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: 6HN exceeded the German Market which returned 8.5% over the past year.
Price Volatility
| 6HN volatility | |
|---|---|
| 6HN Average Weekly Movement | 10.4% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 6HN's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 6HN's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 432 | Rogers Luo | www.everestmedicines.com |
Everest Medicines Limited, a biopharmaceutical company, engages in discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets. Its pipeline includes Nefecon, an oral formulation of budesonide for the treatment of immunoglobulin nephropathy (IgAN); Xerava, a fully synthetic fluorocycline intravenous antibiotic for the treatment of infections caused by susceptible gram-positive, gram-negative, and anaerobic pathogens; Taniborbactam, a beta-lactamase inhibitor (BLI) which is in phase 3 clinical trial for the treatment of patients with serious bacterial infections; and Etrasimod, an oral selective sphingosine 1-phosphate (S1P) receptor modulator which is in phase 3 clinical trial for to treat moderate-to-severe active ulcerative colitis. The company provides Zetomipzomib, an immunoproteasome inhibitor that is in phase 2b clinical trial, for a range of immune mediated disorders, including lupus nephritis; EVER001, a covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor which is in the phase 1b clinical trial for the treatment of renal diseases; and mRNA platform therapeutic vaccines for cancer and autoimmune diseases.
Everest Medicines Limited Fundamentals Summary
| 6HN fundamental statistics | |
|---|---|
| Market cap | €1.50b |
| Earnings (TTM) | -€139.60m |
| Revenue (TTM) | €55.47m |
27.0x
P/S Ratio-10.7x
P/E RatioIs 6HN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6HN income statement (TTM) | |
|---|---|
| Revenue | CN¥418.55m |
| Cost of Revenue | CN¥101.53m |
| Gross Profit | CN¥317.02m |
| Other Expenses | CN¥1.37b |
| Earnings | -CN¥1.05b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.28 |
| Gross Margin | 75.74% |
| Net Profit Margin | -251.64% |
| Debt/Equity Ratio | 10.9% |
How did 6HN perform over the long term?
See historical performance and comparison